Max Planck Institute of Psychiatry , 80804 Munich, Germany.
J Med Chem. 2014 Nov 26;57(22):9473-9. doi: 10.1021/jm501086v. Epub 2014 Nov 7.
B(0)AT2, encoded by the SLC6A15 gene, is a transporter for neutral amino acids that has recently been implicated in mood and metabolic disorders. It is predominantly expressed in the brain, but little is otherwise known about its function. To identify inhibitors for this transporter, we screened a library of 3133 different bioactive compounds. Loratadine, a clinically used histamine H1 receptor antagonist, was identified as a selective inhibitor of B(0)AT2 with an IC50 of 4 μM while being less active or inactive against several other members of the SLC6 family. Reversible inhibition of B(0)AT2 was confirmed by electrophysiology. A series of loratadine analogues were synthesized to gain insight into the structure-activity relationships. Our studies provide the first chemical tool for B(0)AT2.
B(0)AT2,由 SLC6A15 基因编码,是一种中性氨基酸转运体,最近与情绪和代谢紊乱有关。它主要在大脑中表达,但关于其功能知之甚少。为了鉴定该转运体的抑制剂,我们筛选了一个包含 3133 种不同生物活性化合物的文库。氯雷他定是一种临床使用的组胺 H1 受体拮抗剂,被鉴定为 B(0)AT2 的选择性抑制剂,IC50 为 4 μM,而对 SLC6 家族的其他几个成员的活性较低或无活性。电生理学证实了 B(0)AT2 的可逆抑制。合成了一系列氯雷他定类似物,以深入了解结构-活性关系。我们的研究为 B(0)AT2 提供了第一个化学工具。